AbbVie Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-14: Reporting owner Donoghoe Nicholas; Form 4; Security Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-02-25: Reporting owner Siatis Perry C; Form 4; Security Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-02-25: Reporting owner Siatis Perry C; Form 4; Security Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-02-25: Reporting owner Siatis Perry C; Form 4; Security Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
ABBV insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas Officer (EVP, CHIEF BUS/STRAT OFFICER) | 4 | Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32,710 0 owned after | $79.02 exercise price | $249.46 | 2026-08-18 |
| 2026-02-25 | Siatis Perry C Officer (EVP, GC AND SECRETARY) | 4 | Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,314 0 owned after | $149.62 | $226.92 | 2026-02-27 |
| 2026-02-25 | Siatis Perry C Officer (EVP, GC AND SECRETARY) | 4 | Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,775 7,774 owned after | $175.28 | $226.92 | 2026-02-27 |
| 2026-02-25 | Siatis Perry C Officer (EVP, GC AND SECRETARY) | 4 | Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,292 14,583 owned after | $192.86 | $226.92 | 2026-02-27 |
| 2026-02-18 | Thakkar Roopal Officer (EVP, R&D and CSO) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,937 21,937 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Purdue David Ryan Officer (SVP, Controller) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,875 4,875 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Stewart Jeffrey Ryan Officer (EVP, CHIEF COMMERCIAL OFFICER) | 4 | Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,812 26,812 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Siatis Perry C Officer (EVP, GC AND SECRETARY) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,500 19,500 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | SALEKI-GERHARDT AZITA Officer (EVP, CHIEF OPERATIONS OFFICER) | 4 | Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,312 20,312 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Crum Demetris D Officer (EVP, CHIEF HR OFFICER) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,406 13,406 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Donoghoe Nicholas Officer (EVP, CHIEF BUS/STRAT OFFICER) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,312 20,312 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Reents Scott T Officer (EVP, CHIEF FINANCIAL OFFICER) | 4 | Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,937 21,937 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
| 2026-02-18 | Michael Robert A. Director, Officer (CHIEF EXECUTIVE OFFICER) | 4 | Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +81,251 81,251 owned after | $230.04 exercise price | $228.72 | 2026-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |